Yoon-Koo Kang Selected Research

Capecitabine (Xeloda)

1/2022	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
4/2021	Corrigendum to 'Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer', [Eur J Canc 51 (2015) 482-488].
5/2018	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
4/2018	Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
11/2017	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
1/2017	Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
5/2016	Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
3/2015	Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
7/2014	Quality of life in the trastuzumab for gastric cancer trial.
4/2014	Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoon-Koo Kang Research Topics

Disease

90	Neoplasms (Cancer) 06/2022 - 12/2002
90	Stomach Neoplasms (Stomach Cancer) 04/2022 - 07/2002
38	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 11/2022 - 06/2005
36	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 05/2008
24	Disease Progression 10/2021 - 04/2008
23	Adenocarcinoma 10/2021 - 07/2002
19	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2006
14	Neutropenia 01/2020 - 10/2007
11	Breast Neoplasms (Breast Cancer) 05/2019 - 06/2004
10	Colorectal Neoplasms (Colorectal Cancer) 02/2014 - 02/2003
7	Fatigue 01/2021 - 01/2009
6	Anemia 01/2021 - 10/2011
6	Vomiting 01/2021 - 01/2005
6	Diarrhea 01/2021 - 07/2010
6	Liver Neoplasms (Liver Cancer) 01/2019 - 05/2008
5	Nausea 01/2021 - 08/2010
5	Exanthema (Rash) 11/2020 - 05/2013
5	Hypertension (High Blood Pressure) 08/2020 - 01/2013
4	Febrile Neutropenia 01/2022 - 07/2010
4	Hepatitis B 11/2020 - 11/2013
4	Lymphoma (Lymphomas) 11/2014 - 01/2003
4	Hand-Foot Syndrome 11/2013 - 10/2004
4	Rectal Neoplasms (Rectal Cancer) 09/2012 - 04/2002
3	Infections 01/2019 - 09/2007
3	Fibrosis (Cirrhosis) 01/2019 - 11/2011
3	Lymphatic Metastasis 04/2018 - 05/2011
3	Thrombocytopenia (Thrombopenia) 01/2017 - 11/2013
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 10/2007
2	Edema (Dropsy) 01/2021 - 10/2011
2	Hemorrhage 01/2021 - 04/2019
2	Asthenia 08/2020 - 07/2014
2	Ascites 08/2020 - 01/2018
2	Pneumonia (Pneumonitis) 01/2020 - 01/2017
2	Necrosis 04/2019 - 10/2015
2	Liver Diseases (Liver Disease) 01/2019 - 05/2008

Drug/Important Bio-Agent (IBA)

42	Imatinib Mesylate (Gleevec)FDA Link 11/2022 - 06/2005
30	Capecitabine (Xeloda)FDA Link 01/2022 - 07/2003
28	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 08/2002
25	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 01/2009
18	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 04/2008
17	Docetaxel (Taxotere)FDA Link 10/2021 - 07/2002
14	Biomarkers (Surrogate Marker)IBA 06/2022 - 07/2011
14	NivolumabIBA 04/2022 - 06/2017
14	Trastuzumab (Herceptin)FDA Link 04/2022 - 08/2010
14	Fluorouracil (Carac)FDA LinkGeneric 05/2018 - 08/2002
12	PlatinumIBA 04/2022 - 05/2005
12	Sunitinib (Sutent)FDA Link 11/2019 - 07/2011
12	Irinotecan (Camptosar)FDA LinkGeneric 01/2018 - 04/2008
10	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 05/2005
9	Pharmaceutical PreparationsIBA 01/2022 - 01/2009
7	Tyrosine Kinase InhibitorsIBA 10/2021 - 12/2011
7	Monoclonal AntibodiesIBA 01/2021 - 01/2009
7	RamucirumabIBA 01/2021 - 10/2017
7	taxaneIBA 01/2019 - 08/2004
6	regorafenibIBA 10/2021 - 01/2013
6	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2021 - 01/2016
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2008
6	Leucovorin (Folinic Acid)FDA Link 01/2020 - 02/2003
6	Bevacizumab (Avastin)FDA Link 05/2018 - 01/2009
6	Everolimus FDA Link 01/2017 - 12/2013
5	BilirubinIBA 04/2021 - 02/2008
5	ParaffinIBA 05/2017 - 05/2004
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2016 - 01/2009
5	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 05/2004
5	Cetuximab (Erbitux)FDA Link 05/2013 - 01/2009
4	AlbuminsIBA 12/2021 - 04/2015
4	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2021 - 07/2012
4	Phosphotransferases (Kinase)IBA 01/2021 - 05/2009
4	ErbB Receptors (EGF Receptor)IBA 01/2020 - 01/2012
4	thiamine triphosphorate (TTP)IBA 01/2016 - 12/2007
4	AnthracyclinesIBA 04/2012 - 08/2004
3	pembrolizumabIBA 01/2022 - 01/2019
3	Alkaline PhosphataseIBA 12/2021 - 04/2015
3	avapritinibIBA 10/2021 - 01/2021
3	AntigensIBA 01/2021 - 01/2003
3	pertuzumabIBA 05/2019 - 10/2018
3	Immunoglobulin G (IgG)IBA 01/2019 - 12/2017
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 05/2017 - 10/2013
3	human ERBB2 proteinIBA 01/2016 - 08/2010
3	Biological ProductsIBA 04/2012 - 04/2008
3	Vinorelbine (Navelbine)FDA LinkGeneric 12/2006 - 08/2004
2	ProdigyIBA 01/2022 - 10/2021
2	margetuximabIBA 04/2021 - 01/2020
2	S-1 plus cisplatinIBA 01/2021 - 01/2020
2	LigandsIBA 01/2021 - 10/2015
2	SteroidsIBA 11/2020 - 01/2016
2	Immune Checkpoint InhibitorsIBA 01/2020 - 06/2017
2	fisogatinibIBA 12/2019 - 12/2019
2	Ado-Trastuzumab EmtansineIBA 01/2019 - 01/2017
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019 - 07/2012

Therapy/Procedure

80	Drug Therapy (Chemotherapy) 04/2022 - 04/2002
66	Therapeutics 04/2022 - 04/2002
15	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 10/2004
12	Adjuvant Chemotherapy 01/2022 - 06/2004
8	Gastrectomy 10/2021 - 01/2007
6	Radiotherapy 03/2015 - 04/2002
5	Neoadjuvant Therapy 01/2022 - 09/2006
4	Aftercare (After-Treatment) 01/2020 - 06/2005
3	Drug Tapering 11/2020 - 01/2012
2	Salvage Therapy 01/2022 - 12/2006